Comprehensive Nano - Post Market Clinical Follow-Up Study
← catalyst calendarNCT03423953 · readout in 1,442 d
Sponsored by Zimmer Biomet (industry) · ZBH — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
194estimated
Sites
5
Countries
Austria, Canada, South Korea +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2013-10-30 | actual | When the study began enrolling |
| Primary completion | 2030-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-07-31 | estimated | The whole study's end, after follow-up |
| First posted | 2018-02-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Osteoarthritis
- Avascular Necrosis
- Rheumatoid Arthritis
- Revision
- Correction of Functional Deformity
Intervention
- Device: Comprehensive Nano
Primary outcome
what the primary-completion date above is the date OFSurvivorship
measured 10 years
Permalink · ZBH's whole pipeline · Catalyst calendar · Every registered study · What changed